Discover the detailed record of transactions filed by MAHON PAUL A, Executive Vice President, General Counsel, and Corporate Secretary. Director active across 1 companies, notably UNITED THERAPEUTICS Corp. Cumulatively, 49 filings have been recorded. Total volume traded: €108k. The latest transaction was filed on 16 June 2022 — Levée d'options. Regulator: SEC (Form 4). The full history is openly available.
25 of 49 declarations
Paul A. Mahon is a long-serving legal executive at United Therapeutics Corp, where he serves as Executive Vice President, General Counsel, and Corporate Secretary. The company’s leadership biography states that he has held the roles of General Counsel and Corporate Secretary since United Therapeutics was founded in 1996. He joined the company full-time in 2001 as Senior Vice President, General Counsel, and Corporate Secretary, and was promoted to Executive Vice President in 2003. Before joining full-time, he had already supported United Therapeutics from its inception in 1996 as principal and managing partner of a law firm focused on technology and media law. His career path points to deep legal and governance expertise, especially in corporate compliance, entity management, securities-related matters, and board support within a publicly traded biotechnology company. In a regulated industry such as biotechnology, a senior legal officer typically plays a central role in corporate governance, regulatory oversight, disclosure processes, contract strategy, and coordination with senior management and the board of directors. Mahon’s long tenure suggests continuity, institutional memory, and a detailed understanding of the company’s evolution and governance priorities. The sources reviewed do not attribute specific standalone strategic decisions to him, so it is most accurate to describe his contributions in general terms: legal leadership, governance oversight, and sustained executive support for the company’s long-term development.